|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Enlyton, Ltd. Awarded National Cancer Institute SBIR Phase I Contract for Tumor Targeting Agent for SPECT Imaging of Cancer
9/18/2012 9:59:37 AM
COLUMBUS, Ohio--(BUSINESS WIRE)--Enlyton, Ltd., a technology leader in the development of cancer-specific tumor targeting agents for use in molecular imaging, has been awarded a Phase I Small Business Innovation Research (SBIR) contract in the amount of $249,525 from the National Cancer Institute (NCI). The Phase I contract, which will cover approximately 10% of the total project cost, will be used to complete pre-clinical development of Enlyton’s antibody-based tumor targeting agent for SPECT imaging of adenocarcinomas (e.g., colorectal, esophageal, stomach, lung, ovarian, pancreatic).
|
|
|
|
|
|
|
|
|
|
|